Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety follow-up study of lutetium (177Lu) vipivotide tetraxetan in adult participants with prostate cancer
NL-OMON59643Phase 4Recruiting
- Sponsor
- Novartis
- Start
- Aug 2025
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lutetium lu 177 vipivotide tetraxetan in prostate cancer (PCa), sponsored by Novartis. Primary endpoints: Selected adverse events and serious adverse events and Laboratory changes. Started Aug 2025; status: recruiting.
02
Drugs
lutetium lu 177 vipivotide tetraxetan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON59643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59643.